Asthma Therapeutics Market to Grow at a CAGR of 7.7% from 2025 to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Asthma Therapeutics Market Covering 2025–2034?

The asthma therapeutics market size has experienced significant expansion in recent years. Its valuation is anticipated to climb from $30.63 billion in 2024 to $33.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical growth can be linked to heightened awareness concerning asthma management, the increasing utilization of inhalers and nebulizers, the rising incidence of allergic asthma due to pollution, burgeoning government initiatives for respiratory health, and the developing healthcare infrastructure in emerging economies.

The asthma therapeutics market is projected to experience substantial growth in the upcoming years. This market is anticipated to reach a valuation of $44.53 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is primarily driven by factors such as the increasing demand for biologics in asthma treatment, a heightened focus on personalized medicine, the expanding adoption of digital inhalers and smart health devices, a rising prevalence of pediatric asthma, and increased investment in research and development for novel therapeutics. Significant trends anticipated within this period include advancements in biologic therapies for severe asthma, sophisticated inhaler technologies with digital tracking functionalities, the development of individualized asthma treatment plans, innovations in drug-delivery mechanisms, and the integration of artificial intelligence and wearable devices for asthma monitoring.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

Which Major Market Drivers Are Shaping The Future Of The Asthma Therapeutics Market?

The rising occurrence of asthma is anticipated to drive expansion within the asthma therapeutics market. Asthma is defined as a chronic condition leading to inflammation and swelling of the respiratory passages, which in turn constricts the tubes transporting air from the nose and mouth to the lungs. This growing prevalence of asthma stems from a rise in pollutants that irritate the airways, thereby increasing the likelihood of developing the condition. Asthma treatments aid in managing the condition through controlling inflammation in the airways, alleviating symptoms, and preventing acute asthma episodes. Medications for long-term control, such as inhaled corticosteroids, work to diminish chronic inflammation, whereas rapid-acting drugs like bronchodilators offer immediate symptom relief during acute attacks. As an illustration, figures from April 2024, reported by Asthma + Lung UK, an England-based charity assisting individuals with lung conditions, revealed that asthma-related fatalities in England rose from 1,146 in 2021 to 1,236 in 2022. Consequently, the expanding occurrence of asthma is fueling the market growth for asthma therapeutics.

What Are The Major Segment Categories Driving The Asthma Therapeutics Market Growth?

The asthma therapeutics market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)

2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications

3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide

2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol

3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast

4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline

5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab

6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

Which Key Trends Are Expected To Influence The Asthma Therapeutics Market In The Coming Years?

Leading companies in the asthma therapeutics market are concentrating on developing innovative products, such as fixed-dose combination (FDC) drugs, to boost treatment effectiveness and enhance patient compliance. An FDC drug is a pharmaceutical preparation containing two or more active ingredients combined into a single dosage form, like a tablet or inhaler, intended for treating a specific condition. For example, in June 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced a new fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, for asthma treatment. Indacaterol serves as a long-acting beta-agonist (LABA) that aids in relaxing airway muscles, while Mometasone is an inhaled corticosteroid (ICS) that reduces lung inflammation. This specific FDC aims to provide improved symptom management and convenience via once-daily dosing, thereby enhancing treatment adherence among individuals with moderate to severe asthma.

Who Are The Major Companies Operating In The Asthma Therapeutics Market?

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, ALK-Abello, Mylan N.V., Whanin Pharmaceutical, Mitsubishi Tanabe Pharma, Allergan plc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

How Does The Asthma Therapeutics Market Perform Across Key Geographic Regions?

North America was the largest region in the asthma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Asthma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25702&type=smp

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2025, By The Business Research Company

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795